Xiaobin Hou^*1, Tinghui Li^†1, Zhipeng Ren^*, Yang Liu^*

Oncology Research, Vol.24, No.4, pp. 247-253, 2016, DOI:10.3727/096504016X14652175055765

Abstract Mutation of breast cancer 2, early onset (BRCA2) has been identified as a vital risk factor for esophageal cancer (EC). To date, several proteins have been reported as BRCA2-interacting proteins and are associated with multiple biological processes. This study's aim was to identify a novel interactive protein of BRCA2 and to explore its functional roles in EC. A yeast two-hybrid screening was performed to identify a novel BRCA2-interacting protein. Glutathione-S-transferase (GST) pull-down analysis was performed to find out how the binding domain of BRCA2 interacts with LIM domains containing 1 (LIMD1). The interaction between LIMD1… More >

NADIA Z. SHAABAN¹, NASHWA K. IBRAHIM², HELEN N. SAADA², FATMA H. EL-RASHIDY¹, HEBATALLAH M. SHAABAN³, NERMEEN M. ELBAKARY^2,*, AHMAD S. KODOUS^1,2,*

Oncology Research, Vol.30, No.6, pp. 269-276, 2022, DOI:10.32604/or.2022.027277

Abstract Background: MicroRNAs (miRs) are small (19–25 nucleotides), non-protein coding RNAs that regulate gene expression, and thus play essential roles in cell cycle progression. The evidence has demonstrated that the expression of several miRs is dysregulated in human cancer. Methods: The study includes 179 female patients and 58 healthy women Patients were identified as luminal A, B, Her-2/neu, and basal-like, as well as classified into I, II, and III stages. Analysis of the expression fold change of miR-21 and miR-34a with molecular markers, including the oncogene Bcl-2 (B-cell lymphoma 2) and the tumor suppressor genes BRCA1 (breast cancer More >

Neslihan Duzkale^1,*, Nilnur Eyerci²

Oncologie, Vol.22, No.3, pp. 161-166, 2020, DOI:10.32604/oncologie.2020.014116

Abstract BRCA1 and BRCA2 tumor suppressor genes are responsible for a quarter of hereditary breast cancers. Double heterozygous (DH) pathogenic variant carrier status in these genes is an extremely rare condition, especially in non-Askenazi individuals. We report a woman patient with bilateral breast cancer that carries DH disease-causing variants in BRCA1/2 genes. The 45-year-old patient who was followed up with the diagnosis of metachronous bilateral breast cancer was diagnosed with cancer at the age of 39 and 43, respectively. BRCA1/2 genes of the patient were evaluated using Next-Generation Sequencing. In the patient, the c.2800C>T (p.Gln934Ter) pathogenic variant in BRCA1… More >